2025年3月3日 · We are a commercial stage oncology innovator seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and chronic graft-versus-host disease.

Find the latest Syndax Pharmaceuticals, Inc. (SNDX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Join us in this immersive gaming universe where cutting-edge technology meets unparalleled gameplay. Each game offers unique experiences, rich storytelling, and the chance to earn rewards. Become a part of the Syndicate and dive into a world of adventure, strategy, and community. Join us and be part of the revolution in gaming! Explore.

We are dedicated to reimagining how cancer is treated and focused on developing first-in-class solutions that support patient journeys. We have a proven ability to advance innovative and differentiated cancer programs and a strong record of adhering to scientific excellence, following promising clinical data and real-world utilization.

Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in …

Find the latest press releases and updates from Syndax Pharmaceuticals, a leading biopharmaceutical company developing innovative cancer therapies.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

SyndicateX Marketplace is the world's first and largest web2 + web3 marketplace for game-based NFTs and crypto collectibles. Access, browse, buy, and use NFTs using SyndicateX Marketplace.

#药闻简讯# 2024 年 12 月 9 日， $Syndax (SNDX)$ 是一家商业阶段的生物制药公司，致力于开发创新的癌症疗法产品线，今天宣布了来自 Revuforj 的 AUGMENT-101 试验的更多积极数据® (revumenib) 用于治疗复发或难治性 (R/R) 突变型 NPM1 (mNPM1) 急性骨髓细胞白血病 (AML) 以及 revumenib... Syndax (SNDX) 2024-12-21 06:05. $Syndax (SNDX)$ 8-K Current report, item 5.02 Accession Number: 0000950170-24-139121 Act: 34 Size: 153 KB 网页链接.

1 天前 · Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was...